(Yicai Global) Aug. 18 -- Chinese vaccine maker CanSino is rushing to conclude the worldwide third-phase clinical trials of its Covid-19 vaccine, co-developed with a team from the Academy of Military Sciences, after the pair received the country’s first Covid-19 vaccine patent last week.

The company is in contact with countries around the world to carry out third-phase multi-regional clinical trials of its recombinant adenovirus vaccine Ad5-nCoVV as soon as possible, CanSino said today.

A team of scientists from the Academy of Military Sciences of the Chinese People’s Liberation Army and CanSino Biologics were granted a patent by the State Intellectual Property Office for their co-developed Covid-19 vaccine on Aug. 11, despite third-phase clinical trials not yet being completed, the academy said yesterday.

Only after the third phase trials have been completed can a company apply to take the product to market.

The reviewing process for the Covid-19 vaccine can only begin after the global third-phase clinical trials end, the China Economic Net reported today, citing Liu Jingzhen, chairman of the China National Pharmaceutical Group. The jab is expected to be available by the end of the year.

Tianjin-based CanSino [HKG:6185] was trading down 5.92 percent at HKD206.60 (USD26.66) this afternoon, after gains of almost 20 percent yesterday.

Editor: Kim Taylor